Patent · US Active

Prodrugs and uses thereof

US11840560B2 · kind B2 · utility

0Cited by

5References

1Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Patrick James Knerr · Plainfield, US
Brian Finan · Bloomington, US

Key dates

Filing date	Jan 20, 2023
Grant date	Dec 12, 2023
Priority date	—
Expiry date	Jan 20, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.